ENDP - Endo adds over 27% after favorable trial verdict

• Generic drugmaker erased losses on Friday to add more than 27% after the company announced a that a federal jury in Chicago, Illinois issued a favorable verdict in an antitrust trial regarding its 2010 settlement with Amneal Pharmaceuticals ( AMRX ).
• Endo ( NASDAQ: ENDP ) subsidiaries, Endo Pharmaceuticals Inc. and Endo Health Solutions Inc. were involved in multiple lawsuits in which plaintiffs alleged among other things, that the agreement Amneal ( AMRX ) formerly known as Impax over the pain therapy Opana ER violated the antitrust laws.
• The trial that began in June ended today with a verdict in favor of Endo on all counts, the company said in a statement.
• The verdict confirms that the agreement “was procompetitive and enabled Impax to come to market with its generic version of Opana ER years earlier than otherwise would have been permitted," Endo's ( ENDP ) Chief Legal Officer Matthew J. Maletta remarked.

For further details see: